News
NCNA
0.9606
+2.44%
0.0229
Weekly Report: what happened at NCNA last week (1026-1030)?
Weekly Report · 11/02 09:51
Weekly Report: what happened at NCNA last week (1019-1023)?
Weekly Report · 10/26 09:51
Weekly Report: what happened at NCNA last week (1012-1016)?
Weekly Report · 10/19 09:51
Weekly Report: what happened at NCNA last week (1005-1009)?
Weekly Report · 10/12 09:54
Weekly Report: what happened at NCNA last week (0928-1002)?
Weekly Report · 10/05 09:54
NuCana Wins Key European Patent for Lead Cancer Drug NUC-7738
TipRanks · 09/30 12:28
NuCana announces grant of composition-of-matter patent for NUC-7738 in Europe
TipRanks · 09/30 12:10
NuCana Says European Patent Office Grants Patent Covering Composition Of Matter For NUC-7738
Benzinga · 09/30 12:03
Weekly Report: what happened at NCNA last week (0921-0925)?
Weekly Report · 09/28 09:50
Weekly Report: what happened at NCNA last week (0914-0918)?
Weekly Report · 09/21 09:51
Weekly Report: what happened at NCNA last week (0907-0911)?
Weekly Report · 09/14 09:54
Weekly Report: what happened at NCNA last week (0831-0904)?
Weekly Report · 09/07 09:50
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/31 17:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/31 12:06
Weekly Report: what happened at NCNA last week (0824-0828)?
Weekly Report · 08/31 09:54
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/28 21:06
NuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"
Benzinga · 08/28 20:00
Weekly Report: what happened at NCNA last week (0817-0821)?
Weekly Report · 08/24 09:55
Weekly Report: what happened at NCNA last week (0810-0814)?
Weekly Report · 08/17 09:56
NuCana Files Q2 2026 Results and Updates U.S. Registration Statements
TipRanks · 08/13 20:53
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.